No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing

Research output: Contribution to journalJournal articleResearchpeer-review

  • Douglas F Easton
  • Fabienne Lesueur
  • Brennan Decker
  • Kyriaki Michailidou
  • Jun Li
  • Jamie Allen
  • Craig Luccarini
  • Karen A Pooley
  • Mitul Shah
  • Manjeet K Bolla
  • Qin Wang
  • Joe Dennis
  • Jamil Ahmad
  • Ella R Thompson
  • Francesca Damiola
  • Maroulio Pertesi
  • Catherine Voegele
  • Noura Mebirouk
  • Nivonirina Robinot
  • Geoffroy Durand
  • Nathalie Forey
  • Robert N Luben
  • Shahana Ahmed
  • Kristiina Aittomäki
  • Hoda Anton-Culver
  • Volker Arndt
  • Caroline Baynes
  • Matthias W Beckman
  • Javier Benitez
  • David Van Den Berg
  • William J Blot
  • Natalia V Bogdanova
  • Bojesen, Stig Egil
  • Hermann Brenner
  • Jenny Chang-Claude
  • Kee Seng Chia
  • Ji-Yeob Choi
  • Don M Conroy
  • Angela Cox
  • Simon S Cross
  • Kamila Czene
  • Hatef Darabi
  • Peter Devilee
  • Mikael Eriksson
  • Peter A Fasching
  • Jonine Figueroa
  • Henrik Flyger
  • Florentia Fostira
  • Montserrat García-Closas
  • Graham G Giles
  • Australian Ovarian Cancer Study Group

BACKGROUND: BRCA1 interacting protein C-terminal helicase 1 (BRIP1) is one of the Fanconi Anaemia Complementation (FANC) group family of DNA repair proteins. Biallelic mutations in BRIP1 are responsible for FANC group J, and previous studies have also suggested that rare protein truncating variants in BRIP1 are associated with an increased risk of breast cancer. These studies have led to inclusion of BRIP1 on targeted sequencing panels for breast cancer risk prediction.

METHODS: We evaluated a truncating variant, p.Arg798Ter (rs137852986), and 10 missense variants of BRIP1, in 48 144 cases and 43 607 controls of European origin, drawn from 41 studies participating in the Breast Cancer Association Consortium (BCAC). Additionally, we sequenced the coding regions of BRIP1 in 13 213 cases and 5242 controls from the UK, 1313 cases and 1123 controls from three population-based studies as part of the Breast Cancer Family Registry, and 1853 familial cases and 2001 controls from Australia.

RESULTS: The rare truncating allele of rs137852986 was observed in 23 cases and 18 controls in Europeans in BCAC (OR 1.09, 95% CI 0.58 to 2.03, p=0.79). Truncating variants were found in the sequencing studies in 34 cases (0.21%) and 19 controls (0.23%) (combined OR 0.90, 95% CI 0.48 to 1.70, p=0.75).

CONCLUSIONS: These results suggest that truncating variants in BRIP1, and in particular p.Arg798Ter, are not associated with a substantial increase in breast cancer risk. Such observations have important implications for the reporting of results from breast cancer screening panels.

Original languageEnglish
JournalJournal of Medical Genetics
Pages (from-to)298-309
Number of pages12
Publication statusPublished - May 2016

    Research areas

  • Journal Article

ID: 171996457